Skip to main content

Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients

Quality of Life Research volume 26, pages 3409–3419 (2017)Cite this article

Abstract

The purpose of this study is to assess the measurement properties of EQ-5D-5L compared to EQ-5D-3L in psoriasis patients.

Methods

A cross-sectional survey was carried out at an academic dermatology clinic in Hungary. Psoriasis patients completed the EQ-5D-3L, EQ-5D-5L and Dermatology Life Quality Index (DLQI) questionnaires, and Psoriasis Area and Severity Index (PASI) was assessed. The UK value sets were used to calculate the 3L and 5L index scores. We tested the feasibility, ceiling effect, redistribution properties, the level of inconsistency and informativity (Shannon and Shannon Evenness indices). Spearman’s rank-order correlations were performed between EQ-5D, EQ VAS, DLQI and PASI scores. Known-groups validity was evaluated by comparing age groups, clinical subtypes and treatment groups.

Results

Mean age of the 238 patients was 47 years, and 36.6% of them received biological therapy. Mean EQ-5D index score was 0.77 (SD: 0.26) with the 3L and 0.84 (SD: 0.19) with the 5L. The overall ceiling effect decreased from 37.1 (3L) to 32.9% (5L). Shannon index improved significantly for most dimensions, but Shannon Evenness index improved only in three dimensions. Compared to the 3L, the 5L version confirmed a better convergent validity with PASI, but not with the DLQI. Known-groups validity was equally demonstrated both for the 5L and 3L.

Conclusions

The EQ-5D-5L seems to improve measurement properties by reducing ceiling effects, strengthening correlations with PASI and improving informativity. Follow-up studies are needed to test responsiveness and reliability in psoriasis.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Michalek, I. M., Loring, B., & John, S. M. (2017). A systematic review of worldwide epidemiology of psoriasis. Journal of the European Academy of Dermatology and Venereology, 31(2), 205–212.

    CAS  Article  PubMed  Google Scholar 

  2. Boehncke, W. H., & Schon, M. P. (2015). Psoriasis. Lancet, 386(9997), 983–994.

    CAS  Article  PubMed  Google Scholar 

  3. Ahmed, N., Prior, J. A., Chen, Y., Hayward, R., Mallen, C. D., & Hider, S. L. (2016). Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study. Clinical Rheumatology, 35(12), 3069–3073.

    Article  PubMed  Google Scholar 

  4. Frieder, J., & Ryan, C. (2016). Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol, 151(6), 678–693.

    PubMed  Google Scholar 

  5. Gelfand, J. M. (2016). Psoriasis, Type 2 diabetes mellitus, and obesity: Weighing the evidence. JAMA Dermatology, 152(7), 753–754.

    Article  PubMed  PubMed Central  Google Scholar 

  6. van der Voort, E. A., Wakkee, M., Veldt-Kok, P., Darwish Murad, S., & Nijsten, T. (2016). Enhanced liver fibrosis test (ELF) in psoriasis, psoriatic arthritis and rheumatoid arthritis patients: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP). British Journal Dermatology, 30, 7.

    Google Scholar 

  7. Mortezavi, M., Thiele, R., & Ritchlin, C. (2015). The joint in psoriatic arthritis. Clinical and Experimental Rheumatology, 33(5 Suppl 93), S20–S25.

    PubMed  Google Scholar 

  8. de Korte, J., Sprangers, M. A., Mombers, F. M., & Bos, J. D. (2004). Quality of life in patients with psoriasis: a systematic literature review. Journal of Investigative Dermatology Symposium Proceedings, 9(2), 140–147.

    Article  Google Scholar 

  9. Obradors, M., Blanch, C., Comellas, M., Figueras, M., & Lizan, L. (2016). Health-related quality of life in patients with psoriasis: a systematic review of the European literature. Quality of Life Research, 25(11), 2739–2754.

    Article  PubMed  Google Scholar 

  10. Moller, A. H., Erntoft, S., Vinding, G. R., & Jemec, G. B. (2015). A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat Outcome Meas, 6, 167–177.

    PubMed  PubMed Central  Google Scholar 

  11. Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., Jr., & Reboussin, D. M. (1999). Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology, 41(3 Pt 1), 401–407.

    CAS  Article  PubMed  Google Scholar 

  12. Ellis, C. N., Reiter, K. L., Wheeler, J. R., & Fendrick, A. M. (2002). Economic analysis in dermatology. Journal of the American Academy of Dermatology, 46(2), 271–283.

    Article  PubMed  Google Scholar 

  13. Gutknecht, M., Krensel, M., & Augustin, M. (2016). Health economic analyses of psoriasis management: A systematic literature search. Archives of Dermatological Research, 308(9), 601–616.

    Article  PubMed  Google Scholar 

  14. Pereira, F. R., Basra, M. K., Finlay, A. Y., & Salek, M. S. (2012). The role of the EQ-5D in the economic evaluation of dermatological conditions and therapies. Dermatology, 225(1), 45–53.

    CAS  Article  PubMed  Google Scholar 

  15. EuroQol, G. (1990). EuroQol–a new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208.

    Article  Google Scholar 

  16. Brooks, R. (1996). EuroQol: the current state of play. Health Policy, 37(1), 53–72.

    CAS  Article  PubMed  Google Scholar 

  17. Devlin, N. J., & Krabbe, P. F. (2013). The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ, 14(Suppl 1), S1–S3.

    Article  PubMed  Google Scholar 

  18. Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  19. Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Quality of Life Research, 22(7), 1717–1727.

    CAS  Article  PubMed  Google Scholar 

  20. Feng, Y., Devlin, N., & Herdman, M. (2015). Assessing the health of the general population in England: How do the three- and five-level versions of EQ-5D compare? Health and Quality of Life Outcomes, 13, 171.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Ferreira, L. N., Ferreira, P. L., Ribeiro, F. P., & Pereira, L. N. (2016). Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults. Health and Quality of Life Outcomes, 14, 89.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Golicki, D., Niewada, M., Karlinska, A., Buczek, J., Kobayashi, A., Janssen, M. F., et al. (2015). Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients. Quality of Life Research, 24(6), 1555–1563.

    Article  PubMed  Google Scholar 

  23. Greene, M. E., Rader, K. A., Garellick, G., Malchau, H., Freiberg, A. A., & Rolfson, O. (2015). The EQ-5D-5L improves on the EQ-5D-3L for health-related quality-of-life assessment in patients undergoing total hip arthroplasty. Clinical Orthopaedics and Related Research, 473(11), 3383–3390.

    Article  PubMed  Google Scholar 

  24. Jia, Y. X., Cui, F. Q., Li, L., Zhang, D. L., Zhang, G. M., Wang, F. Z., et al. (2014). Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. Quality of Life Research, 23(8), 2355–2363.

    CAS  Article  PubMed  Google Scholar 

  25. Pan, C. W., Sun, H. P., Wang, X., Ma, Q., Xu, Y., Luo, N., et al. (2015). The EQ-5D-5L index score is more discriminative than the EQ-5D-3L index score in diabetes patients. Quality of Life Research, 24(7), 1767–1774.

    Article  PubMed  Google Scholar 

  26. Pickard, A. S., De Leon, M. C., Kohlmann, T., Cella, D., & Rosenbloom, S. (2007). Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Medical Care, 45(3), 259–263.

    Article  PubMed  Google Scholar 

  27. Yfantopoulos, J. N., & Chantzaras, A. E. (2016). Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece. The European Journal of Health Economics, 18, 519–531.

    Article  PubMed  Google Scholar 

  28. Yfantopoulos, J., Chantzaras, A., & Kontodimas, S. (2017). Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. Archives of Dermatological Research, 309(5), 357–370.

    Article  PubMed  Google Scholar 

  29. Conner-Spady, B. L., Marshall, D. A., Bohm, E., Dunbar, M. J., Loucks, L., Al Khudairy, A., et al. (2015). Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement. Quality of Life Research, 24(7), 1775–1784.

    Article  PubMed  Google Scholar 

  30. Janssen, M. F., Birnie, E., Haagsma, J. A., & Bonsel, G. J. (2008). Comparing the standard EQ-5D three-level system with a five-level version. Value Health, 11(2), 275–284.

    Article  PubMed  Google Scholar 

  31. Kim, S. H., Kim, H. J., Lee, S. I., & Jo, M. W. (2012). Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Quality of Life Research, 21(6), 1065–1073.

    Article  PubMed  Google Scholar 

  32. Pattanaphesaj, J., & Thavorncharoensap, M. (2015). Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health and Quality of Life Outcomes, 13, 14.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Pickard, A. S., Wilke, C. T., Lin, H. W., & Lloyd, A. (2007). Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics, 25(5), 365–384.

    Article  PubMed  Google Scholar 

  34. Sakthong, P., Sonsa-Ardjit, N., Sukarnjanaset, P., & Munpan, W. (2015). Psychometric properties of the EQ-5D-5L in Thai patients with chronic diseases. Quality of Life Research, 24(12), 3015–3022.

    Article  PubMed  Google Scholar 

  35. Scalone, L., Ciampichini, R., Fagiuoli, S., Gardini, I., Fusco, F., Gaeta, L., et al. (2013). Comparing the performance of the standard EQ-5D 3L with the new version EQ-5D 5L in patients with chronic hepatic diseases. Quality of Life Research, 22(7), 1707–1716.

    Article  PubMed  Google Scholar 

  36. Ali, F. M., Cueva, A. C., Vyas, J., Atwan, A. A., Salek, M. S., Finlay, A. Y., et al. (2017). A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. British Journal of Dermatology, 176(3), 577–593.

    CAS  Article  PubMed  Google Scholar 

  37. Dubois Declercq, S., & Pouliot, R. (2013). Promising new treatments for psoriasis. Scientific World Journal, 2013, 980419.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ritchlin, C. T., & Krueger, J. G. (2016). New therapies for psoriasis and psoriatic arthritis. Current Opinion in Rheumatology, 28(3), 204–210.

    CAS  Article  PubMed  Google Scholar 

  39. Yang, Y., Brazier, J., & Longworth, L. (2015). EQ-5D in skin conditions: an assessment of validity and responsiveness. The European Journal of Health Economics, 16(9), 927–939.

    Article  PubMed  Google Scholar 

  40. Fredriksson, T., & Pettersson, U. (1978). Severe psoriasis–oral therapy with a new retinoid. Dermatologica, 157(4), 238–244.

    CAS  Article  PubMed  Google Scholar 

  41. van Hout, B., Janssen, M. F., Feng, Y. S., Kohlmann, T., Busschbach, J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health, 15(5), 708–715.

    Article  PubMed  Google Scholar 

  42. Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.

    CAS  Article  PubMed  Google Scholar 

  43. Devlin, N., Shah, K., Feng, Y., Mulhern, B., & van Hout, B. (2016). Valuing health-related quality of life: An EQ-5D-5L value set for England. Research Paper 16/01. Retrieved March 27 2017 from https://eq-5dpublications.euroqol.org/download?id=0_60043&fileId=59836.

  44. Rencz, F., Gulacsi, L., Drummond, M., Golicki, D., Prevolnik Rupel, V., Simon, J., et al. (2016). EQ-5D in central and eastern europe: 2000–2015. Quality of Life Research, 25(11), 2693–2710.

    Article  PubMed  Google Scholar 

  45. Finlay, A. Y., & Khan, G. K. (1994). Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210–216.

    CAS  Article  PubMed  Google Scholar 

  46. Basra, M. K., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008). The dermatology life quality index 1994–2007: A comprehensive review of validation data and clinical results. British Journal of Dermatology, 159(5), 997–1035.

    CAS  PubMed  Google Scholar 

  47. Lewis, V., & Finlay, A. Y. (2004). 10 years experience of the Dermatology Life Quality Index (DLQI). Journal of Investigative Dermatology Symposium Proceedings, 9(2), 169–180.

    Article  Google Scholar 

  48. Hagg, D., Sundstrom, A., Eriksson, M., & Schmitt-Egenolf, M. (2015). Decision for biological treatment in real life is more strongly associated with the psoriasis area and severity index (PASI) than with the dermatology life quality index (DLQI). Journal of the European Academy of Dermatology and Venereology, 29(3), 452–456.

    CAS  Article  PubMed  Google Scholar 

  49. Pathirana, D., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., Nast, A., et al. (2009). European S3-guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 23(Suppl 2), 1–70.

    Article  PubMed  Google Scholar 

  50. Wakkee, M., Thio, H. B., Spuls, P. I., de Jong, E. M., & Nijsten, T. (2008). Evaluation of the reimbursement criteria for biological therapies for psoriasis in the Netherlands. British Journal of Dermatology, 158(5), 1159–1161.

    CAS  Article  PubMed  Google Scholar 

  51. Mrowietz, U., Kragballe, K., Reich, K., Spuls, P., Griffiths, C. E. M., Nast, A., et al. (2011). Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research, 303(1), 1–10.

    CAS  Article  PubMed  Google Scholar 

  52. Rencz, F., Baji, P., Gulacsi, L., Karpati, S., Pentek, M., Poor, A. K., et al. (2016). Discrepancies between the dermatology life quality index and utility scores. Quality of Life Research, 25(7), 1687–1696.

    Article  PubMed  Google Scholar 

  53. Rencz, F., Kemeny, L., Gajdacsi, J. Z., Owczarek, W., Arenberger, P., Tiplica, G. S., et al. (2015). Use of biologics for psoriasis in Central and Eastern European countries. Journal of the European Academy of Dermatology and Venereology, 29(11), 2222–2230.

    CAS  Article  PubMed  Google Scholar 

  54. Gottlieb, A. B., & Armstrong, A. W. (2013). Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting. Journal of Rheumatology, 40(8), 1428–1433.

    Article  PubMed  Google Scholar 

  55. Mease, P. J. (2011). Measures of psoriatic arthritis: Tender and swollen joint assessment, psoriasis area and severity index (PASI), nail psoriasis severity index (NAPSI), modified nail psoriasis severity index (mNAPSI), Mander/Newcastle enthesitis index (MEI), leeds enthesitis index (LEI), spondyloarthritis research consortium of Canada (SPARCC), Maastricht ankylosing spondylitis enthesis score (MASES), Leeds dactylitis index (LDI), patient global for psoriatic arthritis, dermatology life quality index (DLQI), psoriatic arthritis quality of life (PsAQOL), functional assessment of chronic illness therapy-fatigue (FACIT-F), psoriatic arthritis response criteria (PsARC), psoriatic arthritis joint activity index (PsAJAI), disease activity in psoriatic arthritis (DAPSA), and composite psoriatic disease activity index (CPDAI). Arthritis Care Research, 63(Suppl 11), S64–S85.

    Article  PubMed  Google Scholar 

  56. Janssen, M. F., Birnie, E., & Bonsel, G. J. (2007). Evaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon’s indices. Quality of Life Research, 16(5), 895–904.

    Article  PubMed Central  Google Scholar 

  57. Shannon, C. E. (1948). The mathematical theory of communication. The Bell System Technical Journal, 27, 379–423.

    Article  Google Scholar 

  58. Shannon, C. E., & Weaver, W. (1949). The Mathematical Theory of Communication (pp. 104–107). Urbana: University of Illinois Press.

    Google Scholar 

  59. Swinscow, T., & Campbell, M. (2002). Statistics at square one. London, United Kingdom: BMJ.

    Google Scholar 

  60. Heredi, E., Rencz, F., Balogh, O., Gulacsi, L., Herszenyi, K., Hollo, P., et al. (2014). Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: A cross-sectional study in psoriasis from Hungary. The European Journal of Health Economics, 15(Suppl 1), S111–S119.

    Article  PubMed  Google Scholar 

  61. Moradi, M., Rencz, F., Brodszky, V., Moradi, A., Balogh, O., & Gulacsi, L. (2015). Health status and quality of life in patients with psoriasis: An Iranian cross-sectional survey. Archives of Iranian Medicine, 18(3), 153–159.

    PubMed  Google Scholar 

  62. Rencz, F., Brodszky, V., Péntek, M., Balogh, O., Remenyik, É., Szegedi, A., et al. (2014). Disease burden of psoriasis associated with psoriatic arthritis in Hungary. Orvosi Hetilap, 155(48), 1913–1921.

    Article  PubMed  Google Scholar 

  63. Rencz, F., Hollo, P., Karpati, S., Pentek, M., Remenyik, E., Szegedi, A., et al. (2015). Moderate to severe psoriasis patients’ subjective future expectations regarding health-related quality of life and longevity. Journal of the European Academy of Dermatology and Venereology, 29(7), 1398–1405.

    CAS  Article  PubMed  Google Scholar 

  64. Janssen, B., Lloyd, A., & Wailoo, A. (2016). Increasing EuroQol (EQ-5D) from 3 to 5 levels: implications for users—Does “new” mean “better”?, Congress: ISPOR 19th Annual European Congress. Vienna, Austria, Oct 29–Nov 2, 2016. Retrieved March 26, 2017 from https://www.ispor.org/Event/ReleasedPresentations/2016Vienna

  65. Versteegh, M. M., Vermeulen, K. M., Evers, S. M. A. A., de Wit, G. A., Prenger, R., & Stolk, E. A. (2016). Dutch tariff for the five-level version of EQ-5D. Value Health, 19(4), 343–352.

    Article  Google Scholar 

  66. Puzenat, E., Bronsard, V., Prey, S., Gourraud, P. A., Aractingi, S., Bagot, M., et al. (2010). What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. Journal of the European Academy of Dermatology and Venereology, 24(Suppl 2), 10–16.

    Article  PubMed  Google Scholar 

  67. Nast, A., & Schmitt, J. (2013). Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 68(6), 1040–1041.

    Article  PubMed  Google Scholar 

  68. Blome, C., Beikert, F. C., Rustenbach, S. J., & Augustin, M. (2013). Mapping DLQI on EQ-5D in psoriasis: transformation of skin-specific health-related quality of life into utilities. Archives of Dermatological Research, 305(3), 197–204.

    Article  PubMed  Google Scholar 

  69. Norlin, J. M., Steen Carlsson, K., Persson, U., & Schmitt-Egenolf, M. (2012). Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. British Journal of Dermatology, 166(4), 797–802.

    CAS  Article  PubMed  Google Scholar 

  70. Szende, A., & Nemeth, R. (2003). Health-related quality of life of the Hungarian population. Orvosi Hetilap, 144(34), 1667–1674.

    PubMed  Google Scholar 

  71. Baji, P., Brodszky, V., Rencz, F., Boncz, I., Gulacsi, L., & Pentek, M. (2015). Health status of the Hungarian population between 2000-2010. Orvosi Hetilap, 156(50), 2035–2044.

    Article  PubMed  Google Scholar 

  72. Gudjonsson, J. E., & Elder, J. T. (2007). Psoriasis: epidemiology. Clinics in Dermatology, 25(6), 535–546.

    Article  PubMed  Google Scholar 

  73. Hungarian Central Statistical Office. Population by education and age group. (2011). Retrieved March 26, 2017 from http://www.ksh.hu/nepszamlalas/docs/tables/regional/01/01_1_1_4_1_en.xls

  74. Hagg, D., Eriksson, M., Sundstrom, A., & Schmitt-Egenolf, M. (2013). The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS ONE, 8(5), e63619.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Kojanova, M., Fialova, J., Cetkovska, P., Gkalpakiotis, S., Jircikova, J., Dolezal, T., et al. (2017). Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. International Journal of Dermatology, 56(4), 428–434.

    CAS  Article  PubMed  Google Scholar 

  76. Swinburn, P., Lloyd, A., Boye, K. S., Edson-Heredia, E., Bowman, L., & Janssen, B. (2013). Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health, 16(8), 1156–1162.

    Article  PubMed  Google Scholar 

  77. Pickard, A. S., Gooderham, M., Hartz, S., & Nicolay, C. (2017). EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. Journal of Medical Economics, 20(1), 19–27.

    Article  PubMed  Google Scholar 

  78. Buchholz, I., Thielker, K., Feng, Y. S., Kupatz, P., & Kohlmann, T. (2015). Measuring changes in health over time using the EQ-5D 3L and 5L: a head-to-head comparison of measurement properties and sensitivity to change in a German inpatient rehabilitation sample. Quality of Life Research, 24(4), 829–835.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Authors are grateful to Elly Stolk (EuroQol Group, Scientific Team Leader) and Miklós Sárdy (Semmelweis University, Department of Dermatology, Venereology and Dermatooncology) for their valuable comments on the manuscript.

Funding

Márta Péntek’s work in this study was supported by an independent research grant from her employer Corvinus University of Budapest (‘Kutatási Kiválóság Díj 2016’—Research Excellence Award 2016).

Author information

Affiliations

  1. Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Mária utca 41, 1085, Budapest, Hungary

    Adrienn Katalin Poór, Bernadett Hidvégi, Péter Holló & Sarolta Kárpáti

  2. Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, 1093, Budapest, Hungary

    Fanni Rencz, Valentin Brodszky, László Gulácsi, Zsuzsanna Beretzky & Márta Péntek

  3. Doctoral School of Business and Management, Corvinus University of Budapest, Fővám tér 8, 1093, Budapest, Hungary

    Zsuzsanna Beretzky

Authors
  1. Adrienn Katalin Poór
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fanni Rencz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valentin Brodszky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. László Gulácsi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zsuzsanna Beretzky
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bernadett Hidvégi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Péter Holló
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sarolta Kárpáti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Márta Péntek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fanni Rencz.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study protocol was approved by the Semmelweis University Regional and Institutional Committee of Science and Research Ethics (Reference No. 58./2015).

Informed consent

Informed consent was obtained from all participants included in the study.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Poór, A.K., Rencz, F., Brodszky, V. et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life Res 26, 3409–3419 (2017). https://doi.org/10.1007/s11136-017-1699-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11136-017-1699-x

Keywords

  • EQ-5D-3L
  • EQ-5D-5L
  • Psoriasis
  • Health-related quality of life
  • Measurement properties
  • Psychometrics